Better Medications Adherence Lowers Cardiovascular Events, Stroke, and All-Cause Mortality Risk: A Dose-Response Meta-Analysis

Overview

Journal J Cardiovasc Dev Dis

Specialty Cardiology & Vascular Diseases

Date 2021 Nov 25

PMID 34821699

Citations 13

Authors

Mengying Liu

Guowei Zheng

Xiting Cao

Xinyu Chang

Ningning Zhang

Ge Liang

Anran Wang

Yan Yu

Yongli Yang

Yang Zhao

Xuezhong Shi

Dongsheng Hu

Jie Lu

Affiliations

Soon will be listed here.

Abstract

Aims: We investigated the association between vascular medication adherence, assessed by different methods, and the risk of cardio-cerebrovascular events and all-cause mortality.

Methods: A meta-analysis with a systematic search of PubMed, Web of Science, EMBASE, and Cochrane databases from inception date to 21 June 2021 was used to identify relevant studies that had evaluated the association between cardiovascular medication adherence levels and cardiovascular events (CVEs), stroke, and all-cause mortality risks. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects meta-analysis. Restricted cubic splines were used to model the dose-response association.

Results: We identified 46 articles in the dose-response meta-analysis. The dose-response analysis indicated that a 20% increment in cardiovascular medication, antihypertensive medication, and lipid-lowering medication adherence level were associated with 9% (RR: 0.91, 95% CI 0.88-0.94), 7% (RR 0.93, 95% CI: 0.84-1.03), and 10% (RR 0.90, 95% CI: 0.88-0.92) lowers risk of CVEs, respectively. The reduced risk of stroke respectively was 16% (RR: 0.84, 95% CI: 0.81-0.87), 17% (RR 0.83, 95% CI: 0.78-0.89), and 13% (RR 0.87, 95% CI: 0.84-0.91). The reduced risk of all-cause mortality respectively was 10% (RR: 0.90, 95% CI: 0.87-0.92), 12% (RR 0.88, 95% CI: 0.82-0.94), and 9% (RR 0.91, 95% CI: 0.89-0.94).

Conclusions: A better medication adherence level was associated with a reduced risk of cardio-cerebrovascular events and all-cause mortality.

Citing Articles

Pharmacist-supported electronic outreach to address medication nonadherence for Medicare Advantage enrollees.

Virrueta N, Valdiviez V, Beutel T, Titus O, Peauroi S, Billups S J Manag Care Spec Pharm. 2025; 31(1):33-41.

PMID: 39745844 PMC: 11695840. DOI: 10.18553/jmcp.2025.31.1.33.

Achievement of LDL-Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA-AP Study: LDL-Cholesterol Goals in Primary Care.

Cinza-Sanjurjo S, Barrios V, Fierro-Gonzalez D, Polo-Garcia J, Pallares-Carratala V Cardiovasc Ther. 2025; 2024:4227941.

PMID: 39742006 PMC: 11236467. DOI: 10.1155/2024/4227941.

Risk of Adverse Health Outcomes in Patients with Poor Adherence to Cardiovascular Medication Treatment: A Systematic Review.

Malachias M, Kaiser S, Albuquerque D, Brandao A, Sposito A, Moura L Arq Bras Cardiol. 2024; 121(10):e20240469.

PMID: 39607399 PMC: 11634203. DOI: 10.36660/abc.20240469.

Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid-Lowering Therapy: A Multinational Economic Evaluation Study.

Cho J, Wilson F, Chaikledkaew U, Chen Y, Phrommintikul A, Diaz-Aguilera M J Am Heart Assoc. 2024; 13(22):e037792.

PMID: 39548005 PMC: 11681399. DOI: 10.1161/JAHA.124.037792.

Nonadherence to Cardiovascular Drugs Predicts Risk for Non-Arthritic Anterior Ischemic Optic Neuropathy: A Large-Scale National Study.

Hammud A, Haviv Y, Walter E, Amitai N, Kerman T, Leeman S J Clin Med. 2024; 13(16).

PMID: 39200811 PMC: 11355576. DOI: 10.3390/jcm13164670.

References

Cohuet G, Struijker-Boudier H . Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther. 2005; 111(1):81-98. DOI: 10.1016/j.pharmthera.2005.09.002. View

Hudson M, Rahme E, Richard H, Pilote L . Comparison of measures of medication persistency using a prescription drug database. Am Heart J. 2006; 153(1):59-65. DOI: 10.1016/j.ahj.2006.10.018. View

Bekkering G, Harris R, Thomas S, Mayer A, Beynon R, Ness A . How much of the data published in observational studies of the association between diet and prostate or bladder cancer is usable for meta-analysis?. Am J Epidemiol. 2008; 167(9):1017-26. DOI: 10.1093/aje/kwn005. View

Hartemink N, Boshuizen H, Nagelkerke N, Jacobs M, van Houwelingen H . Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2. Am J Epidemiol. 2006; 163(11):1042-52. DOI: 10.1093/aje/kwj141. View

Ni Chroinin D, Asplund K, Asberg S, Callaly E, Cuadrado-Godia E, Diez-Tejedor E . Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke. 2013; 44(2):448-56. DOI: 10.1161/STROKEAHA.112.668277. View

Sun X, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky M . Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020; 21(9):1173-1187. DOI: 10.1016/S1470-2045(20)30327-2. View

Chen S, Lee H, Chang K, Hung J, Chen H, Wu C . Low Persistence of Antithrombotic Agents is Associated with Poor Outcomes after First-ever Acute Ischemic Stroke. Acta Neurol Taiwan. 2020; 28(4):95-118. View

Choudhry N, Kronish I, Vongpatanasin W, Ferdinand K, Pavlik V, Egan B . Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension. 2021; 79(1):e1-e14. PMC: 11485247. DOI: 10.1161/HYP.0000000000000203. View

Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C . Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38):2940-8. DOI: 10.1093/eurheartj/eht295. View

10.

Bosworth H, Granger B, Mendys P, Brindis R, Burkholder R, Czajkowski S . Medication adherence: a call for action. Am Heart J. 2011; 162(3):412-24. PMC: 3947508. DOI: 10.1016/j.ahj.2011.06.007. View

11.

Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8. View

12.

Roth G, Johnson C, Abajobir A, Abd-Allah F, Abera S, Abyu G . Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70(1):1-25. PMC: 5491406. DOI: 10.1016/j.jacc.2017.04.052. View

13.

Xu T, Yu X, Ou S, Liu X, Yuan J, Chen Y . Statin Adherence and the Risk of Stroke: A Dose-Response Meta-Analysis. CNS Drugs. 2017; 31(4):263-271. DOI: 10.1007/s40263-017-0420-5. View

14.

Vrijens B, de Geest S, Hughes D, Przemyslaw K, Demonceau J, Ruppar T . A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5):691-705. PMC: 3403197. DOI: 10.1111/j.1365-2125.2012.04167.x. View

15.

van Dongen M, Aarnio K, Martinez-Majander N, Pirinen J, Sinisalo J, Lehto M . Use of antihypertensive medication after ischemic stroke in young adults and its association with long-term outcome. Ann Med. 2018; 51(1):68-77. PMC: 7857461. DOI: 10.1080/07853890.2018.1564358. View

16.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

17.

Yeo S, Toh M, Lee S, Seet R, Wong L, Yau W . Impact of medication nonadherence on stroke recurrence and mortality in patients after first-ever ischemic stroke: Insights from registry data in Singapore. Pharmacoepidemiol Drug Saf. 2020; 29(5):538-549. DOI: 10.1002/pds.4981. View

18.

ODonnell M, Chin S, Rangarajan S, Xavier D, Liu L, Zhang H . Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016; 388(10046):761-75. DOI: 10.1016/S0140-6736(16)30506-2. View

19.

Giannopoulos S, Katsanos A, Tsivgoulis G, Marshall R . Statins and cerebral hemodynamics. J Cereb Blood Flow Metab. 2012; 32(11):1973-6. PMC: 3494001. DOI: 10.1038/jcbfm.2012.122. View

20.

Corrao G, Rea F, Monzio Compagnoni M, Merlino L, Mancia G . Protective effects of antihypertensive treatment in patients aged 85 years or older. J Hypertens. 2017; 35(7):1432-1441. DOI: 10.1097/HJH.0000000000001323. View